Risk and Incidence of Atypical Femur Fracture Associated with Bisphosphonates: A Systematic Review Protocol
Abstract
Objective: : To describe the protocol for a systematic review and meta-analysis that will evaluate the association between bisphosphonate use and the risk of atypical femoral fractures (AFFs), as well as estimate the incidence of AFFs among adults with osteoporosis. Methods This protocol will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook recommendations. Electronic searches will be conducted in PubMed, Embase, and Scopus from database inception to the final search date. Cohort and case-control studies evaluating oral or intravenous bisphosphonates in adults with osteoporosis will be included. Risk of bias will be assessed using the ROBINS-I tool. When appropriate, random-effects meta-analyses will be performed to estimate pooled risk ratios or incidence rate ratios, and single-arm meta-analyses will be used to estimate the incidence of AFFs per 100,000 person-years. Subgroup, sensitivity, and meta-regression analyses will be conducted when feasible. Results This review is expected to provide updated and methodologically robust evidence regarding the risk and incidence of atypical femoral fractures associated with bisphosphonate therapy, while exploring potential sources of heterogeneity across studies. The findings of this systematic review and meta-analysis are expected to support evidence-based clinical decision-making regarding the long-term use of bisphosphonates for osteoporosis and contribute…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.